Nanatinostat
- Generic Name
- Nanatinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19FN6O2
- CAS Number
- 1256448-47-1
- Unique Ingredient Identifier
- YTL7A418KQ
- Background
Nanatinostat is under investigation in clinical trial NCT00697879 (Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours).
- Associated Conditions
- -
- Associated Therapies
- -
Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Viracta Therapeutics, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05166577
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath